财务数据和关键指标变化 - 公司在第一季度实现总收入1,239,000美元,同比增长4.7%,主要由于CGuard EPS销售增长6.7% [13][29] - 毛利增加251,000美元或206%至373,000美元,毛利率从10.3%提升至30.1%,主要由于存货减记减少184,000美元和收入增加71,000美元 [31][32] - 经营费用增加146,000美元或3.2%至4,754,000美元,主要由于C-Guardians FDA研究、销售营销和监管费用增加 [33] - 净亏损4,256,000美元,每股亏损0.53美元,较上年同期4,481,000美元、每股亏损0.57美元有所改善 [34] - 截至3月31日,现金及等价物为12,900,000美元,较12月31日的17,800,000美元有所下降 [34] 各条业务线数据和关键指标变化 - CGuard EPS销售增长6.7%,是公司收入增长的主要驱动因素 [13][29] - 公司在第二季度重新获得CE认证后,及时恢复了对欧洲市场的供货,消化了积压的订单 [29][49] 各个市场数据和关键指标变化 - 公司在欧洲市场拥有超过25%的市场份额,部分地区超过80% [17] - 由于CE认证临时失效,公司在第一季度前半段无法向欧洲市场供货,导致积压了约600,000美元的订单 [29][30] 公司战略和发展方向及行业竞争 - 公司完成了113.6百万美元的转型性融资,由知名医疗科技投资者领投,为公司未来发展提供了强大支持 [7][26][27][28] - 融资将用于推进CGuard在美国的监管审批和商业化,建立美国业务运营和销售渠道 [10][11][21] - 公司正在开发CGuard Prime和SwitchGuard两款新的送药系统,以满足更广泛的医生群体需求,提升CGuard在内膜剥脱术和颈动脉支架术中的使用 [22][23][24] - 公司致力于推动内膜剥脱术向内膜支架术的转变,CGuard作为最佳植入物在这一转变中发挥关键作用 [18] 管理层对经营环境和未来前景的评论 - 公司暂时失去CE认证对销售造成了一定影响,但团队努力确保了产品供应,维护了患者的治疗需求 [13][14][17] - 公司有信心通过新产品发布和销售网络建设,加快内膜剥脱术向内膜支架术的转变,实现市场份额增长 [18][24] - 公司认为本季度收入增长不能完全反映市场真实需求,未来有望恢复正常增长 [30] 问答环节重要的提问和回答 问题1 **Benjamin Haynor 提问** 融资是否会加速公司其他产品如MGuard的研发和新适应症的开发 [39] **Marvin Slosman 回答** 融资为公司提供了资金支持,可以加快推进CGuard在急性卒中等新适应症的临床试验和监管审批 [40][42] 问题2 **Benjamin Haynor 提问** 公司在美国市场的商业化准备工作情况如何 [43] **Marvin Slosman 回答** 公司已经聘请了资深商业主管Shane Gleason负责美国市场的准备工作,包括与医生群体的沟通和销售团队的建设等 [45][46] 问题3 **Benjamin Haynor 提问** 公司是否已经消化了第一季度因CE认证失效而积压的订单 [48] **Marvin Slosman 回答** 公司已经优先满足了主要分销商和客户的订单需求,并将继续努力消化剩余的积压订单,恢复正常的销售节奏 [49]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2123838 (State or other jurisdiction ...

InspireMD, Inc. (NASDAQ:NSPR) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Chuck Padala - IR, LifeSci Advisors Marvin Slosman - CEO Craig Shore - CFO Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Good morning, and welcome to the InspireMD Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to Chuck Padala with LifeSci Advisors. Thank ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2123838 (State or other jurisdiction of (I.R.S. Employer incorporation or orga ...

InspireMD, Inc. (NASDAQ:NSPR) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Chuck Padala - IR, LifeSci Advisors Marvin Slosman - CEO Craig Shore - CFO Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Good morning, and welcome to the InspireMD Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this ...

InspireMD, Inc. (NASDAQ:NSPR) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Chuck Padala - Investor Relations Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Good morning, and welcome to the InspireMD Second Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the presentation, there will be an opportunity to ask questions. [ ...

InspireMD, Inc. (NASDAQ:NSPR) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Chuck Padala - Investor Relations Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings and welcome to InspireMD First Quarter 2022 Earnings Call. [Operator Instructions] At this time, I???d like to turn the call over to your host, Chuck Padala, LifeSci Advisors. Thank you. You may begin. Chu ...

InspireMD, Inc. (NASDAQ:NSPR) Q4 2021 Earnings Conference Call March 8, 2022 8:30 AM ET Company Participants Chuck Padala - Managing Director, LifeSci Advisors Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Operator Greetings, and welcome to InspireMD Fourth Quarter and Full-Year 2021 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentati ...

InspireMD, Inc. (NASDAQ:NSPR) Q3 2021 Earnings Conference Call November 9, 2021 8:30 AM ET Company Representatives Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer David Holmes - LifeSci Advisors Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings! Welcome to InspireMD, Third Quarter 2021 Earnings Call. At this time all participants are in a listen-only mode. [Operator Instructions]. Please note, this conference is being recorded. I will now tu ...

Start Time: 8:30 January 1, 0000 8:51 AM ET InspireMD, Inc. (NASDAQ:NSPR) Q2 2021 Earnings Conference Call August 10, 2021, 08:30 AM ET Company Participants Marvin Slosman - CEO Craig Shore - CFO Jules Abraham - CORE IR Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the InspireMD Second Quarter 2021 Financial Results and Corporate Update Conference Call. At this time, all participants are in a list ...